The specter of generic rivalry has consistently loomed over copyright’s famous drug, Sildenafil, triggering questions about the outlook of related pharmaceutical holdings. While first times saw substantial gains, the patent end has opened the way for discounted alternatives, potentially reducing earnings and posing a real danger for shareholders